Introduction: Lacosamide has been used in epilepsy patients in the United States, Europe
and Asia since it was approved by the FDA in 2008. Many patients have benefited from this …

Background: Adverse effects of antiseizure medications (ASMs) remain one of the major
causes of non-adherence. Cosmetic side effects (CSEs) are among the most commonly …

Background Further options for monotherapy are needed to treat newly diagnosed epilepsy
in adults. We assessed the efficacy, safety, and tolerability of lacosamide as a first-line …

Objectives Evaluate long‐term effectiveness and tolerability of brivaracetam in clinical
practice in patients with focal epilepsy. Materials and Methods This was a multicenter …

Background In randomized controlled trials, add-on brivaracetam (BRV) reduced seizure
frequency in patients with drug-resistant focal epilepsy. Studies performed in a naturalistic …

Objective To evaluate efficacy and tolerability of adjunctive lacosamide in children and
adolescents with uncontrolled focal (partial-onset) seizures. Methods In this double-blind …

Objective To assess retention, dosing, efficacy, and safety of perampanel in a large cohort of
patients with epilepsy during routine clinical care. Methods PROVE was a retrospective, non …

Introduction Lacosamide is licensed for the treatment of focal seizures in both adults and
children, however there is little information available on its adverse reactions. Using the FDA …

Objective To evaluate the effectiveness and tolerability of lacosamide added to one or two
antiepileptic drugs (AEDs) in the treatment of patients with brain tumor–related epilepsy …

To report the efficacy and tolerability of lacosamide as an add-on treatment in patients with
gliomas and uncontrolled seizures despite conventional antiepileptic drugs (AEDs). We …